Pharmacokinetics / Pharmacodynamics

#Cell line development #Drug discovery #Lab analytics #Monoclonal antibodies #Pharmacokinetics / Pharmacodynamics

Analysis in the lab: Advancing drug discovery

Learn about the critical role analytical tools and equipment have in helping to advance drug discovery research in this DDW eBook sponsored by Sartorius. This eBook covers: Opinions on the major trends in lab analytics. Measuring the pharmacokinetics of monoclonal antibodies. Best practices in cell line development Access the… Read More

#DDW eBooks #Intelligence

Human brain
#Clinical trials #Neuroscience #Pharmacokinetics / Pharmacodynamics

Patients dosed in Phase I trial assessing psychiatric disorders 

Beckley Psytech has dosed the first cohort of volunteers in a clinical trial exploring the safety of its novel formulation of intranasal 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT).  The Phase I study is designed as a double-blind, randomised, single ascending dose study to evaluate the safety and tolerability of a single intranasal dose of… Read More

#News

#Biotechnology #Drug development #Drug discovery #Ingredients / APIs / Fine chemicals #Pharmacokinetics / Pharmacodynamics

Evotec expands UK site into drug discovery & development centre

Evotec is expanding its campus in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus. Adding a new building, which will house up to 100 biologists by the end of the year, will bring together all the key functions for… Read More

#News

#Drug development #Pharmacokinetics / Pharmacodynamics

TherapeutAix teams up with CROs to solve PK/PD challenges

Life sciences consultancy, TherapeutAix, has added contract research organisations (CROs), Alderley Analytical and Peak Proteins to its global R&D network, forming a dedicated and expert team to solve Pharmacokinetics and Pharmacodynamics (PK/PD) challenges faced by clients. Based in Aachen, Germany, TherapeutAix is a biotech consultancy providing services from strategic planning… Read More

#News

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genetics #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Metabolomics #Microbiome #Molecular medicine #Oncology #Patent Law #PCR #Pharmacogenomics #Pharmacokinetics / Pharmacodynamics #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Reigniting Pharmaceutical Innovation Through Holistic Drug Targeting

By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic. Secondly, none of the… Read More

#Archive